Mounjaro Wins Canadian Label Expansion for Cardiovascular Risk Reduction
LLY sits 62% above its 52-week low of $850.51.
Summary
Canada's regulator added a cardiovascular risk reduction indication to Mounjaro, extending the label beyond glycemic control. This is the first ex-US expansion of the CV claim, following the FDA's August 28 approval of Mounjaro to reduce major adverse cardiovascular events in adults with type 2 diabetes. The incremental commercial value is modest next to Lilly's $24.4B quarterly revenue base, but it widens the label moat against Novo Nordisk in a second major market and supports pricing and formulary arguments.
At the time of this announcement, LLY was trading at $1,381.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $850.51 to $1,475.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.